Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Significant Increase in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 4,975 shares, a growth of 895.0% from the November 30th total of 500 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average trading volume of 419,828 shares, the short-interest ratio is currently 0.0 days. Based on an average trading volume of 419,828 shares, the short-interest ratio is currently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Provectus Biopharmaceuticals Stock Down 7.0%

Shares of OTCMKTS:PVCT traded down $0.00 during midday trading on Wednesday, reaching $0.06. The company’s stock had a trading volume of 174,403 shares, compared to its average volume of 235,753. The stock has a fifty day moving average of $0.07 and a 200 day moving average of $0.07. Provectus Biopharmaceuticals has a twelve month low of $0.05 and a twelve month high of $0.12.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.